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Purpose: To evaluate changes in electroretinogram (ERG) response over the course of
multiple sessions of panretinal photocoagulation (PRP) in patients with proliferative diabetic
retinopathy (PRP).
Methods: A prospective cohort study of 11 patients with PDR who required PRP was
conducted. PRP was completed over three sessions. Each patient had five ERGs done:
baseline, 1 week after each PRP session, and 6 weeks after the last session of PRP. Dark-
adapted 0.01 ERG, Dark-adapted 3 ERG, Dark-adapted 10 ERG, Light- adapted 3 ERG, and
Light-adapted 30 Hz flicker ERG were done. The mean change in a- and b-wave amplitudes
as well as implicit times compared to baseline was analyzed.
Results: A significant reduction in peak amplitudes of both a- and b-waves and delay in
latencies were observed in all responses (p<0.05). The absolute amplitude reduction and
delay in latency were higher for scotopic b-waves (p<0.05). The root mean square (RMS) of
Dark-adapted 10.0 ERG (p<0.05) and total mean amplitude changes of a- and b-waves
(p<0.001) were reduced after each laser session; however, the magnitude of change was
not different between the first, second, or third sessions of PRP, and each session showed
a similar deterioration rate of ERG parameters comparing to each other (p=0.4 for RMS and
p=0.2 for total mean amplitude changes). In addition, the results indicated recovery of the
amplitude and latency of ERG waves after 6 weeks from the final treatment (p<0.001)
although not to baseline levels.
Conclusion: ERG findings following PRP show reduced retinal function after each session
which partially recovers by 6 weeks after the completion of therapy. Clinicians should be
mindful of these changes when planning the treatment course for patients with PDR.
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Introduction
Proliferative diabetic retinopathy (PDR) is an important cause of vision loss.1 The
principle treatments for PDR are panretinal photocoagulation (PRP) and, more
recently, intravitreal injections of anti-vascular endothelial growth factor (VEGF)
agents which have both been shown to reduce the risk of vision loss.2 PDR
treatment can utilize PRP, anti-VEGF, or both.2
Laser treatment to the peripheral ischemic retina induces neovascular regression
and reduces angiogenesis;3 however, PRP is also associated with functional con-
sequences including reductions in peripheral and night vision.4 Electroretinograms
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objective measure of retinal function.5 The therapeutic
window for PRP wherein the risk of secondary sequelae
is outweighed by the treatment benefit is not well defined.
Although prior studies have investigated the effect of PRP
on ERG response, post-treatment response was assessed
after completion of full PRP treatment.5–9 The study pre-
sented herein sought to characterize how ERG measures
change over the course of sequential PRP treatments in an
effort to quantify the additive effect of progressive laser
treatment.
Materials and Methods
This prospective cohort study was conducted after attain-
ing Institutional Review Board approval from the Farabi
Eye Hospital, Tehran University of Medical Sciences. The
study adhered to the Declaration of Helsinki. Written
informed consent was obtained from all the patients.
Patients with a history of unilateral high-risk PDR demon-
strated on fluorescein angiography, were included. Eyes
with PDR had a diabetic retinopathy severity scale (DRSS)
of 61 −71 and a DRSS of 47–53 in the fellow eye. Patients
with greater severity scores that might require additional
interventions and patients with significant symmetry in
DRSS between their two eyes were excluded from the
analysis. Furthermore, patients with a prior history of
intravitreal injections, retinal lasers, significant media opa-
city, ocular abnormality that might impact ERG measure-
ments (including more than 3 diopters of myopia), prior
history of retinal detachment, center involving diabetic
macular edema (that may require imminent treatment), or
prior history of vitrectomy were excluded from this study.
The purpose of the study was to attempt to isolate the
effect of PRP on ERG measures. The fellow, non-PDR,
eye was used as a control since diabetic retinopathy can
impact ERG measures and there can be a high degree
intra-subject variability.
Patients received three sessions of PRP separated by
1-week intervals. PRP was conducted at the slit lamp using
the Ellex Integre Duo Photocoagulator (Mawson Lakes,
SA, Australia) and a wide field contact lens (Volk
SuperQuad 160 Panfundus lens, Volk Co., Mentor, OH,
USA). Scatter PRP was done with the following settings:
532 nm green wavelength, spot size of 500 μm, duration of
0.1 s, and power of 250 to 400 mW (titrating to achieve
a grey-white burn). Patients received 350–400 spots with
each session. Inferior-inferior/temporal retinal was treated
at the first session followed by nasal and superior-superior
/temporal quadrant.
ERG was performed using the MonPack3 system
(Metrovision, Pérenchies, France). ERGs were done at
baseline (pre-treatment), 1 week after each PRP session,
and 6 weeks after the last PRP treatment. Dark-adapted
0.01 ERG, Dark-adapted 3 ERG, Dark-adapted 10 ERG,
Light-adapted 3 ERG, and Light-adapted 30 Hz flicker
ERG were recorded. ERGs were done in accordance with
International Society for Clinical Electrophysiology of
Vision (ISCEV) standard in an electrically shielded room
to avoid additional sound and noise.10 All ERG tests were
performed by an experienced examiner and the peaks of
the wave amplitude were selected. To quantify the overall
response waveform, root mean square (RMS) was calcu-
lated which was defined as the area under the curve
[amplitude (nV)] in Dark-adapted 10 ERG.
Statistical Analysis
All statistical analysis was performed using IBM SPSS
Statistics for Windows software version 21.0 (IBM Corp.,
Armonk, NY). The mean value of a-wave and b-wave
amplitude, as well as latency, were calculated and compared
between the first and second PRP session, the first and third
PRP sessions, and the second and third PRP sessions using
paired t-test. In addition, the mean changes in the amplitude
and latency of the three different laser sessions were com-
pared with the pre-treatment and 6 weeks post-treatment
sessions using the paired t-test.
Results
Eleven eyes with PDR were included in this study. Nine
subjects were female (82%) and the average age was 57.6±
10.3 years old. Tables 1 and 2 provide summaries of the mean
value and percentage of change in a- and b-waves amplitudes
and latencies following PRP. Seven comparisons were con-
ducted for each ERG parameter: after first session versus pre-
treatment baseline, after second session versus pre-treatment
baseline, after third session versus pre-treatment baseline, after
first session versus after second session, after second session
versus after third session, after third session versus 6 weeks
after third session, and 6 weeks after third session versus pre-
treatment baseline. Of note, no significant changes in ERG
parameters of control contralateral eyes were seen during the
study.
There was a reduction in a- and b-wave amplitude 1 week
after each PRP session on Dark-adapted 3.0, Light-adapted
3.0 and Dark-adapted 10 responses when compared to base-
line ERG and the immediately preceding PRP treatment
(P<0.005). There was a statistically significant increase in
Khojasteh et al Dovepress
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Table 1 Changes in a-Wave, b-Wave, and 30 Hz Flicker in Different Time Points
Type Amplitude Latency
Pair MD(%) SD P-value Pair MD(%) SD P-value
a wave D.A 3 ERG FS and Pre −2.42(10.42) 1.36 <0.001 FS and Pre 0.71(2.22) 1.16 0.041
SS and Pre −4.7(20.31) 1.57 <0.001 SS and Pre 1.36(4.38) 1.63 0.020
TS and Pre −6.05(26.36) 1.54 <0.001 TS and Pre 2.11(6.85) 1.93 0.005
FS and SS −2.28(10.97) 1.2 0.003 FS and SS 0.65(2.07) 0.62 0.003
SS and TS −1.35(7.56) 0.61 0.003 SS and TS 0.75(2.34) 0.58 0.003
1.5M and TS 1.11(6.72) 0.51 0.003 1.5M and TS −0.85(2.51) 0.79 0.003
1.5M and Pre −4.95(21.70) 0.33 0.003 1.5M and Pre 1.26(4.23) 1.25 0.014
L.A 3 ERG FS and Pre −2.34(10.53) 1.23 <0.001 FS and Pre 0.56(2.59) 0.50 0.004
SS and Pre −4.36(19.78) 1.86 <0.001 SS and Pre 1.11(5.04) 0.47 <0.001
TS and Pre −5.52(24.99) 2.36 <0.001 TS and Pre 1.57(7.15) 0.65 <0.001
FS and SS −2.34(10.39) 1.23 0.003 FS and SS 0.55(2.41) 0.39 0.026
SS and TS −2.03(6.62) 0.92 0.003 SS and TS 0.46(1.99) 0.26 0.003
1.5M and TS 0.66(4.16) 0.28 0.003 1.5M and TS −0.55(2.30) 0.22 0.021
1.5M and Pre −5.39(25.13) 1.80 0.003 1.5M and Pre 1.02(4.59) 0.02 0.003
D.A 10 ERG FS and Pre −11.69(8.17) 2.32 <0.001 FS and Pre 0.85(2.89) 0.69 0.002
SS and Pre −24.35(17.2) 4.34 <0.001 SS and Pre 1.50(5.05) 0.70 <0.001
TS and Pre −34.2(23.71) 9.08 <0.001 TS and Pre 2.10(7.12) 0.65 <0.001
FS and SS −11.69(9.63) 2.32 0.003 FS and SS 0.65(2.12) 2.32 0.003
SS and TS −12.65(8.6) 2.76 0.003 SS and TS 0.6(1.99) 0.6 0.003
1.5M and TS 4.14(3.82) 1.29 0.003 1.5M and TS −0.7(2.20) 0.4 0.003
1.5M and Pre −30.07(21.08) 6.81 0.032 1.5M and Pre 1.40(4.71) 1.27 0.003
b wave D.A 0.01 ERG FS and Pre −10.0(9.90) 1.65 <0.001 FS and Pre 3.09(3.22) 2.41 0.002
SS and Pre −20.34(20.19) 1.99 <0.001 SS and Pre 6.95(7.17) 3.51 <0.001
TS and Pre −27.26(27.15) 2.86 <0.001 TS and Pre 10.35(10.64) 4.22 <0.001
FS and SS −10.34(11.44) 1.29 0.003 FS and SS 3.86(3.82) 2.07 0.003
SS and TS −6.93(8.77) 2.04 0.003 SS and TS 3.4(3.23) 1.6 0.003
1.5M and TS 8.54(12.40) 3.37 0.003 1.5M and TS −4.75(4.29) 2.84 0.003
1.5M and Pre −18.72(18.31) 2.67 0.011 1.5M and Pre 5.60(5.71) 1.27 0.003
L.A 3 ERG FS and Pre −6.03(2.95) 3.24 <0.001 FS and Pre 0.47(0.52) 0.26 <0.001
SS and Pre −15.98(7.82) 6.68 <0.001 SS and Pre 1.47(1.61) 0.69 <0.001
TS and Pre −24.45(11.96) 7.19 <0.001 TS and Pre 2.25(2.48) 0.78 <0.001
FS and SS −9.95(5.03) 4.27 0.003 FS and SS 1(1.09) 0.75 0.003
SS and TS −8.46(4.50) 2.7 0.003 SS and TS 0.78(0.85) 0.59 0.003
1.5M and TS 6.86(3.86) 3.67 0.003 1.5M and TS −1.12(1.19) 0.54 0.003
1.5M and Pre −17.40(18.36) 0.54 0.003 1.5M and Pre 0.48(1.12) 0.12 0.004
D.A 3 ERG FS and Pre −7.66(8.04) 3.09 <0.001 FS and Pre 0.19(0.48) 0.35 0.049
SS and Pre −15.02(15.81) 4.26 <0.001 SS and Pre 0.59(1.41) 0.33 <0.001
TS and Pre −21.45(21.00) 4.32 <0.001 TS and Pre 0.99(2.16) 0.31 <0.001
FS and SS −7.35(8.47) 2.35 0.003 FS and SS 0.4(0.93) 0.12 0.003
SS and TS −6.43(8.01) 2.71 0.003 SS and TS 0.4(0.92) 0.13 0.003
1.5M and TS 4.05(5.68) 2.81 0.003 1.5M and TS −0.52(1.19) 0.2 0.003
1.5M and Pre −17.58(8.64) 0.82 0.003 1.5M and Pre 1.15(1.26) 0.14 0.003
D.A 10 ERG FS and Pre −16.56(4.67) 5.89 <0.001 FS and Pre 1.77(3.16) 0.86 <0.001
SS and Pre −34.34(9.76) 7.62 <0.001 SS and Pre 3.51(6.31) 1.22 0.001
TS and Pre −55.34(15.57) 11.01 <0.001 TS and Pre 4.23(7.75) 3.20 <0.001
FS and SS −17.77(5.34) 4.92 0.003 FS and SS 1.74(3.06) 1.2 0.003
SS and TS −21(6.42) 9.22 0.003 SS and TS 0.72(1.36) 3.18 0.050
1.5M and TS 9.03(3.05) 3.91 0.003 1.5M and TS −0.91(1.41) 2.49 0.050
1.5M and Pre −46.31(13.07) 5.76 0.003 1.5M and Pre 3.32(5.94) 0.42 0.049
(Continued)
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a- and b-wave amplitude 6 weeks after the last PRP session
when compared to the ERG taken 1 week after the last PRP
session (P<0.005); however, the amplitudes remained lower
than baseline ERG values (P<0.05). Similarly, a- and b-wave
latencies increased 1 week after each treatment session.
Although the latencies decreased between the last session
of PRP and 6 weeks follow-up ERG, they still remained
longer than baseline ERG values.
Table 1 (Continued).
Type Amplitude Latency
Pair MD(%) SD P-value Pair MD(%) SD P-value
Flicker 30 Hz ERG FS and Pre −4.35(8.43) 1.56 <0.001 FS and Pre 0.55(1.69) 0.21 <0.001
SS and Pre −9.10(17.50) 2.15 <0.001 SS and Pre 1.14(3.46) 0.34 <0.001
TS and Pre −14.00(26.88) 3.25 <0.001 TS and Pre 1.70(5.17) 0.39 <0.001
FS and SS −4.75(9.90) 1.29 0.003 FS and SS 0.58(1.74) 0.18 0.003
SS and TS −4.91(11.41) 1.76 0.003 SS and TS 0.56(1.65) 0.13 0.003
1.5M and TS 6.24(16.58) 1.91 0.003 1.5M and TS −0.91(2.62) 0.3 0.003
1.5M and Pre −7.77(14.84) 0.99 0.001 1.5M and Pre 0.79(2.39) 0.05 0.001
Table 2 Changes in Scotopic and Photopic a-Wave and b-Wave in Different Time Points
Type Amplitude Latency
Pair MD(%) SD P-value Pair MD(%) SD P-value
Scotopic a FS and Pre −7.05(9.89) 5.10 <0.001 FS and Pre 0.78(1.81) 0.94 0.001
SS and Pre −14.52(18.66) 10.55 <0.001 SS and Pre 1.43(4.71) 1.23 <0.001
TS and Pre −20.13(25.3) 15.74 <0.001 TS and Pre −2.10(6.89) 1.41 <0.001
FS and SS −4.29(1.82) 7.50 <0.001 FS and SS 0.48(1.55) 0.76 <0.001
SS and TS −5.53(7.49) 6.05 <0.001 SS and TS 0.70(2.39) 1.05 <0.001
1.5M and TS 3.39(8.43) 6.25 <0.001 1.5M and TS −0.74(2.28) 1.17 <0.001
1.5M and Pre −17.75(21.46) 14.03 <0.001 1.5M and Pre 1.55(5.21) 1.32 <0.001
Photopic a FS and Pre −2.34(15.04) 1.23 <0.001 FS and Pre 0.56(2.18) 0.50 0.004
SS and Pre −4.36(19.78) 1.86 <0.001 SS and Pre 1.11(5.04) 0.47 <0.001
TS and Pre −5.52(24.99) 2.36 <0.001 TS and Pre 1.57(7.15) 0.65 <0.001
FS and SS −1.13(5.05) 2.62 <0.001 FS and SS 0.58(2.68) 0.51 0.001
SS and TS −0.83(3.32) 1.90 <0.001 SS and TS 0.24(1.05) 0.36 <0.001
1.5M and TS 1.08(7.30) 3.36 <0.001 1.5M and TS −0.57(2.38) 0.87 <0.001
1.5M and Pre −4.87(22.70) 2.29 <0.001 1.5M and Pre 1.05(4.72) 0.52 <0.001
Scotopic b FS and Pre −10.86(0.87) 5.87 <0.001 FS and Pre 1.78(5.51) 1.80 <0.001
SS and Pre −23.55(12.59) 9.83 <0.001 SS and Pre 3.98(5.03) 3.12 <0.001
TS and Pre −35.68(18.23) 16.04 <0.001 TS and Pre 5.61(6.96) 4.61 <0.001
FS and SS −8.18(3.95) 18.75 <0.001 FS and SS 1.91(2.23) 4.33 <0.001
SS and TS −8.45(4.77) 16.33 <0.001 SS and TS 0.99(1.04) 3.84 <0.001
1.5M and TS 8.99(5.99) 16.37 <0.001 1.5M and TS −3.60(3.53) 7.46 <0.001
1.5M and Pre −24.66(11.21) 17.95 <0.001 1.5M and Pre 3.36(4.11) 2.80 <0.001
Photopic b FS and Pre −7.66(12.37) 3.09 <0.001 FS and Pre 0.19(0.64) 0.35 0.049
SS and Pre −15.02(15.81) 4.26 <0.001 SS and Pre 0.59(1.41) 0.33 <0.001
TS and Pre −21.45(21) 4.32 <0.001 TS and Pre 0.99(2.16) 0.31 <0.001
FS and SS −4.23(4.40) 9.00 <0.001 FS and SS 0.20(0.48) 0.51 0.001
SS and TS −4.28(3.35) 10.04 <0.001 SS and TS 0.21(0.48) 0.36 <0.001
1.5M and TS 5.83(10.14) 14.1 <0.001 1.5M and TS −018(0.38) 0.87 <0.001
1.5M and Pre −17.39(18.35) 2.38 <0.001 1.5M and Pre 0.60(1.40) 0.22 <0.001
Note: 1.5M= 6 weeks after final treatment.
Abbreviations: FS, First Session; MD, Mean Difference; SD, Standard deviation; SS, Second Session; TS, Third Session.
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A similar pattern was observed on 30 Hz flicker amplitude
and latencies with evidence of reduced function 1 week after
each PRP session with some recovery noted 6 weeks after the
final PRP treatment that did not reach baseline values.
Variations in the mean RMS of amplitude in Dark-
Adapted 10 ERG are shown in Figure 1. Each laser session
resulted in reduction of amplitude RMS (p<0.001) 1 week
after treatment and a relative improvement was seen 6 weeks
after the third treatment session (p<0.05); however, compar-
ing inter-sessions RMS change, the reduction in magnitude
was not different among these three sessions (p=0.4).
ERG changes in scotopic and photopic values are out-
lined in Table 2. Both a- and b-wave amplitudes decreased 1
week after each PRP session but demonstrated recovery at
the final follow-up visit 6 weeks after the last PRP treatment.
Latencies for both a- and b-waves increased 1 week after
each PRP session but decreased at the final ERG measure-
ment. Although there was some recovery in amplitudes and
latencies between the last PRP session and the last ERG 6
weeks post-treatment, these values did not return to baseline.
These variations were significantly higher for absolute
values of b-wave compared to the a-wave (P<0.05).
The percentage change in a- and b-wave amplitudes at
each post-PRP visit when compared to baseline pre-
treatment ERG is outlined in Table 3. When the total mean
changes in percentage were compared, a-wave amplitude
reduction was found to be higher than the b-wave amplitude
reduction. The amplitude changes in Table 3 represent cumu-
lative measurements since retinal tissue changes after each
session sums with preceding treatments. It should be noted
that the difference between sessions involves the summation
of prior retinal tissue loss (resulting in reduced amplitude)
with the possible post-treatment recovery in amplitudes
which may be beginning by the second post-treatment week.
Figure 2 provides a graphical breakdown of ERG
changes in a sample patient from this study.
Time
6 weeks after 
treatment
















Figure 1 Retinal functional changes in D.A 10 ERG test during laser treatment sessions Shown in Root Mean Square (RMS).
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Discussion
PRP is a well-established treatment for PDR11 and has
been shown to reduce the risk of severe vision loss in
patients with high-risk PDR by 50%.12 During PRP light
energy is absorbed by the retinal pigment epithelium
(RPE) and then converted to heat energy, which increases
the temperature of the tissue. This energy destroys the
tissue and leads to the death of retinal cells. The destruc-
tion of ischemic extra-macular retina reduces the VEGF
drive within the retina, thereby limiting the stimulant for
neovascularization.13 Although ultimately beneficial in
reducing vision loss from progressive retinopathy, PRP
does result in retinal tissue damage. Functioning, albeit
ischemic, retina is sacrificed to reduce the risk of more
significant harm from progressive diabetic retinopathy.
The risk of post-PRP macular edema reduced peripheral
vision, and reduced night vision deficits remain
concerns.14
Table 3 The Overall Amplitude Changes in Percentage After Each Laser Session and 1.5 Months After Final Treatment Compared to
Pretreatment Values




P-value P-value of Comparing a- and
b- Amplitude Changes
1 week after F.S −11.6% <0.001 −3.7% <0.001 <0.01
1 week after S.S −19.1% <0.001 −13.4% <0.001 <0.01
1 week after T.S −25.1% <0.001 −18.9% <0.001 <0.01
6 weeks after T.S −21.4% <0.001 −14.5% <0.001 <0.01
Abbreviations: FS, First Session; SS, Second Session; TS, Third Session.
Figure 2 Full-field ERG of a patient enrolled in this study according to ISCEV −2015 standards. The time of ERG recording from baseline (before PRP) to 6 weeks after the
final session of PRP has been shown in columns (A–E). Three upper rows are related to dark-adapted states (DA) and 2 lower rows are related to light-adapted states (LA)
and between them magnified view of DA 10.0 wave changes of this patient over time have been shown in an ellipsoid inset. As have been shown, a- and b-waves amplitude
decrease from baseline to 3ʹrd session after PRP (A–D) and these amplitudes recover and increase 6 weeks after the final session of PRP (E).
Khojasteh et al Dovepress
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ERGs provide an objective and quantifiable measure of
retinal function: a-waves are derived from the cone and
rod cells of the outer photoreceptor layers whereas the
b-waves are generated from the inner retina, predomi-
nantly the Muller and ON-bipolar cells.15
Prior studies have demonstrated loss of ERG amplitude
following PRP, with conflicting results in the relative
changes of a- and b-waves. Liang et al7 and Han et al9
found a greater reduction in b wave absolute amplitudes
than a wave, with Perlman et al8 demonstrating propor-
tional changes in the absolute amplitudes of both waves.
Gjotterberg et al6 demonstrated a greater reduction in the
percentage change of a-wave amplitudes. The results out-
lined herein demonstrated a greater absolute change in
b-wave amplitude, although there was a greater percentage
change in a-wave amplitude.
Reported changes in b-wave amplitudes after PRP vary
considerably. Frank et al16 reported an average decrease in
b-wave amplitude of 40% in their 24 patients 6 weeks after
PRP while also finding that 40% of the outer retina was
destroyed by PRP. In the present study, the average reduc-
tion of amplitude at 6 weeks post-treatment was 21.4% for
a-waves and 14.5% for b-waves. Ogden et al recorded
ERGs of 14 patients with PDR before and 8 weeks after
the PRP17 and found a wide range of variations in post-
treatment ERG values. Liang et al7 examined differences
in ERG response 1 month following argon or xenon arc
laser treatment in patients. Eleven patients had one eye
treated with argon laser and the other with xenon arc laser.
There was a similar reduction in ERG parameters between
eyes treated with either laser unless the burned retinal area
treated with xenon arc laser was more than twice the size
compared to the area treated with argon laser in the con-
tralateral eye. Liang et al7 also found a reduction of
b wave, and to a less extent, a-wave amplitudes regardless
of laser type indicating damage to both the outer and inner
retinal layers following ERG. John and Devi18 performed
PRP on 53 diabetic patients with ERGs taken pre-
treatment, 1 month post-treatment, and 3 months post-
treatment. The authors reported a global loss of retinal
function which was variable and was reflected in the
statistically significant reduction in amplitudes of the
ERG without a significant change in latencies which con-
trasts to the findings of the present study which shows
reduced a- and b-wave amplitudes as well as prolonged
latencies after PRP. The average reduction of amplitude at
3 months was 27.2% for a-waves and 14.4% for b-waves
in John and Devi’s study, while the changes to the implicit
time were not significant.
Imai and Iijima19,20 reported a dramatic reduction in
the amplitude and a delay in the implicit time of rabbit
eyes 1 day after PRP with a partial recovery of amplitude
4 weeks after treatment. The present study demonstrated
partial recovery of the amplitudes and the latencies 6
weeks after the final treatment. Capoferri et al5 performed
ERGs in 16 patients with PDR prior to PRP, in the interval
between laser sessions, within 36 hrs of the final session
and 4 months later. The analysis of the results showed
a significant decrease in the peak amplitudes of both a- and
b-waves in photopic and dark-adapted conditions that
occurred as early as between treatment sessions and
remained depressed at 4-month follow-up. The lack of
recovery in Capoferri et al’s study5 contrasts with the
present findings which demonstrated partial recovery of
retinal function 6 weeks after completion of PRP.
Considering pathophysiology of the PRP, not only func-
tional tissue loss would be occurring, but also the burning
RPE and retina is associated with cytokine release and
subsequent inflammation cascades. Hence, inflammation
and retinal tissue loss are two main components of treat-
ment-related ERG drops. Retinal tissue loss is an irrever-
sible process; however, the inflammation would be
resolved over the time which results in improved ERG
parameters 6 weeks (in this study) after completion of
PRP. It must be noted that glycemic control may affect
the ERG parameters; in this study, glycemic status variable
was controlled indirectly, by consideration of the stage of
diabetic retinopathy through DRSS. One possible explana-
tion for lack of recovery in Capoferri et al’s study5 may be
uncontrolled glycemic status and/or post-laser inflamma-
tion which might affect ERG changes after the completion
of PRP.
There were several limitations to this study including
its small sample size, which was a result of the strict
inclusion criteria. Indeed, considering the small sample
size and the nature of variability in ERG recordings and
interpretations, the study may not be too strong. Also,
future studies may utilize ultrawide field imaging to better
quantify the amount of ablation delivered during PRP
treatments and its correlation to ERG changes.
Comparisons between studies that explore post-PRP
ERG changes are complicated by differences in PRP treat-
ment and ERG testing protocols, including type of ERG
machine, as well as differences in follow-up intervals. Anti-
VEGF therapy is increasingly employed as a treatment for
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PDR, either as monotherapy or, more commonly, as an
adjunct to PRP. PRP remains popular because the treatment
effect is longer than anti-VEGF and because anti-VEGF
therapy requires a high degree of patience compliance for
frequent injections.21 Combination treatment with PRP and
anti-VEGF is a popular treatment option that allows for more
rapid regression of neovascularization via anti-VEGF with
more long-term protection against recurrent neovasculariza-
tion via PRP. Combination PRP and intravitreal ranibizumab
treatment showed less adverse effects on retinal functions
than PRP alone, possibly because less intense PRP treatment
was required.22 PRP is typically titrated to ensure regression
or stabilization of neovascularization, and the ideal amount
of treatment is unknown. In this study, alternations in retinal
function after PRP were demonstrated. These findings help
quantify the degree of ERG loss after each session of
350–400 spots of PRP treatment. A better understanding of
the degree of retinal damage following PRP may be helpful
in determining the ideal amount of laser treatment that bal-
ances regression of retinal neovascularization while mini-
mizing reductions in retinal function.
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